- Home
- CCCC vs LUNG Comparison
CCCC vs LUNG Comparison
Compare CCCC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- LUNG
- Stock Information
- Founded
- CCCC 2015
- LUNG 1995
- Country
- CCCC United States
- LUNG United States
- Employees
- CCCC N/A
- LUNG N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- CCCC Health Care
- LUNG Health Care
- Exchange
- CCCC Nasdaq
- LUNG Nasdaq
- Market Cap
- CCCC 104.4M
- LUNG 106.3M
- IPO Year
- CCCC 2020
- LUNG 2020
- Fundamental
- Price
- CCCC $2.26
- LUNG $3.34
- Analyst Decision
- CCCC Buy
- LUNG Buy
- Analyst Count
- CCCC 3
- LUNG 6
- Target Price
- CCCC $12.00
- LUNG $11.53
- AVG Volume (30 Days)
- CCCC 2.0M
- LUNG 420.0K
- Earning Date
- CCCC 08-04-2025
- LUNG 07-30-2025
- Dividend Yield
- CCCC N/A
- LUNG N/A
- EPS Growth
- CCCC N/A
- LUNG N/A
- EPS
- CCCC N/A
- LUNG N/A
- Revenue
- CCCC $39,783,000.00
- LUNG $87,473,000.00
- Revenue This Year
- CCCC N/A
- LUNG $18.02
- Revenue Next Year
- CCCC N/A
- LUNG $18.17
- P/E Ratio
- CCCC N/A
- LUNG N/A
- Revenue Growth
- CCCC 98.56
- LUNG 19.84
- 52 Week Low
- CCCC $1.09
- LUNG $2.50
- 52 Week High
- CCCC $7.36
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- CCCC 60.73
- LUNG 57.32
- Support Level
- CCCC $2.15
- LUNG $2.99
- Resistance Level
- CCCC $2.53
- LUNG $3.88
- Average True Range (ATR)
- CCCC 0.28
- LUNG 0.34
- MACD
- CCCC 0.02
- LUNG 0.10
- Stochastic Oscillator
- CCCC 62.13
- LUNG 58.46
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.